Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 6/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243687 | 0.89 | CDK9 (0.51) | CDK9CCNT1ADORA3LMNACYP1A2 | |
| SCHEMBL1244349 | 0.88 | CDK9 (0.60) | CDK9CCNT1ADORA3GAALMNA | |
| SCHEMBL4108286 | 0.84 | ADORA3 (0.53) | CDK9CCNT1ADORA3GAASMN1; SMN2 | |
| SCHEMBL1243609 | 0.77 | CDK9 (0.65) | CDK9CCNT1LMNACYP1A2CYP2C19 | |
| SCHEMBL1243712 | 0.76 | CDK9 (0.56) | CDK9CCNT1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL4103963 | 0.75 | EGFR (0.54) | CDK9CCNT1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL4105937 | 0.75 | CDK9 (0.53) | CDK9CCNT1LMNACYP1A2CYP2C19 | |
| SCHEMBL4114830 | 0.74 | CDK9 (0.49) | CDK9CCNT1LMNACYP1A2CYP2C19 | |
| SCHEMBL2015381 | 0.72 | MAPT (0.56) | GAACACNA1HSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL4109070 | 0.72 | PIP4K2C (0.50) | CDK9CCNT1LMNACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | CDK9 39/4885CCNT1 343/4885ADORA3 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.